FDA notes “continued growth” of Orbis collaborative review program, adds EMA as observer
Regulatory NewsJoanne S. Eglovitch
Biologics/ biosimilars/ vaccinesBiotechnologyPharmaceuticalsRegulatory NewsJoanne S. EglovitchBiologics/ biosimilars/ vaccinesBiotechnologyPharmaceuticals